Medicines For Malaria Venture (mmv) - Pharma

Relevant Publications

Novel Compound MMV1804559 from the Global Health Priority Box Exhibits In Vitro and In Vivo Activity against .

Issue Release: 2024

Flucofuron as a Promising Therapeutic Agent against Brain-Eating Amoeba.

Issue Release: 2024

Deconvoluting and derisking QRS complex widening to improve cardiac safety profile of novel plasmepsin X antimalarials.

Issue Release: 2024

A Prodrug Strategy to Reposition Atovaquone as a Long-Acting Injectable for Malaria Chemoprotection.

Issue Release: 2024

Global Health Priority Box─Proactive Pandemic Preparedness.

Issue Release: 2024

Compound management in a virtual research organization: the cornerstone of a reliable MMV discovery engine.

Issue Release: 2024

Discovery of a small-molecule inhibitor of KSHV lytic replication from the MMV Pandemic Response Box.

Issue Release: 2024

msp1, msp2, and glurp genotyping to differentiate Plasmodium falciparum recrudescence from reinfections during prevention of reestablishment phase, Sri Lanka, 2014-2019.

Issue Release: 2024

Synthesis of Deuterated Endochin-Like Quinolones.

Issue Release: 2024

Evaluation of MMV Pandemic Response Box compounds to identify potent compounds against clinically relevant bacterial and fungal clinical isolates .

Issue Release: 2024

Search for novel ATP4 inhibitors from the MMV Pandemic Response Box through a virtual screening approach.

Issue Release: 2023

Phenotypical Screening of an MMV Open Box Library and Identification of Compounds with Antiviral Activity against St. Louis Encephalitis Virus.

Issue Release: 2023

Screening of MMV pandemic response and pathogen box compounds against pan-drug-resistant to identify potent inhibitory compounds.

Issue Release: 2023

Leveraging the MMV Pathogen Box to Engineer an Antifungal Compound with Improved Efficacy and Selectivity against .

Issue Release: 2023

Repurposing the Medicines for Malaria Venture\'s COVID Box to discover potent inhibitors of Toxoplasma gondii, and in vivo efficacy evaluation of almitrine bismesylate (MMV1804175) in chronically infected mice.

Issue Release: 2023

Pandemic Response Box® library as a source of antifungal drugs against Scedosporium and Lomentospora species.

Issue Release: 2023

Development and application of a PBPK modeling strategy to support antimalarial drug development.

Issue Release: 2023

Structure activity relationship and target prediction for ABX464 analogues in Caenorhabditis elegans.

Issue Release: 2023

Screening of the Medicines for Malaria Venture Pandemic Response Box for Discovery of Antivirulent Drug against Pseudomonas aeruginosa.

Issue Release: 2022

Identifying novel drugs with new modes of action for neglected tropical fungal skin diseases (fungal skinNTDs) using an Open Source Drug discovery approach.

Issue Release: 2022

Who Can Participate in Clinical Trials?

What is Geriatric Care in Pharma?

What Causes Adverse Drug Events?

What is a New Drug Application (NDA)?

What is Medication Adherence?

What is Cellular Stress?

How are New Drugs Discovered?

What Should Be Included in Patient Education Materials?

Which Agencies are Involved?

What is an Abbreviated New Drug Application (ANDA)?

Partnered Content Networks

Relevant Topics